Achieving Efficacy and Exploring Indication Expansion for Complement Inhibitors

The complement community is shifting gear, with more companies than ever targeting alternative complement proteins for their therapies, allowing for a larger range of diseases to be targeted.

With more assets in ophthalmology, neurology, and oncology than ever before, the complement-based therapeutics field has everyone asking the same question: which inhibitor will be the next to harness the complement system for the development of groundbreaking therapies?

From the discovery of new pathways to target to post-approval indication expansion, the immunology landscape is primed to capitalize on the huge strides being taken in achieving efficacy and approving the safety profile of complement-based therapeutics.

Join 100+ complement industry leaders, scientists, and clinicians at the premier, end-to-end 8th Complement-Based Drug Development Summit to shape the future of complement-targeted therapies.

URLs:

Tickets: https://go.evvnt.com/2612126-2?pid=91 

Brochure: https://go.evvnt.com/2612126-3?pid=91 

Prices:

Drug Developer Pricing - Conference + 3 Workshops: USD 4197.00,

Drug Developer Pricing - Conference + 2 Workshops: USD 3797.00,

Drug Developer Pricing - Conference + 1 Workshop: USD 3398.00,

Academic Pricing - Conference + 3 Workshops: USD 3597.00,

Academic Pricing - Conference + 2 Workshops: USD 3264.00,

Academic Pricing - Conference + 1 Workshop: USD 2931.00,

Solution and Service Provider Pricing - Conference + 3 Workshops: USD 5097.00,

Solution and Service Provider Pricing - Conference + 2 Workshops: USD 4630.00,

Solution and Service Provider Pricing - Conference + 1 Workshop: USD 4165.00

Speakers: Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, Alex Pellerin, Principal Scientist, Grid Therapeutics, Alexandra Lucas, Founding Scientist, Serpass Biologics, Andrew Cook, Senior Director - Discovery Chemistry, Apellis Pharmaceuticals, Axel Vater, Founder and Chief Scientific Officer, Aptarion biotech AG, Bruce Keyt, Chief Scientific Officer, IGM Biosciences, Edward Patz, Chief Executive Officer, Grid Therapeutics, Emma Persson, Clinical Scientist, Argenx, Hemant Khanna, Vice President of Preclinical Ocular Research, IVERIC bio, Horia Pribiag, Research Scientist, The Broad Institute of MIT and Harvard, James Hamilton, Chief of Discovery and Translational Medicine, Arrowhead Pharmaceuticals Inc., Jeffrey Stavenhagen, Chief Scientific Officer, Dianthus Therapeutics, Karina Yazdanbakhsh, Vice President and Head of Complement Bio Laboratory, New York Blood Center, Karthik Viswanathan, Vice President - Research, Visterra, Lori Taylor, Senior Vice President, Portfolio Strategy and Operations, Annexon Biosciences, Maciej Markiewski, Professor, Texas Tech University Health Sciences Center, Martin Kolev, Associate Director - Complement Science, Apellis Pharmaceuticals, Michael Holers, Professor - Medicine, University of Colorado Denver | Anschutz Medical Campus, Michael Storek, Head of Complement Therapeutics, Sanofi, Nirmal Banda, Professor, University of Colorado Anschutz Medical Campus, Sandra Wymann, Associate Director, CSL Behring, Shiyu Wang, Co-Founder and Chief Scientific Officer, SanegeneBio